Onyx Ph. mit enormen Potential !?!? - 500 Beiträge pro Seite

[Cirrusx4]

Kann mir einer bestätigen, das Onyx ein Kursziel von 100€ hat? Kommt das Kursziel vom Biotech-Report?

Wenn meine Infos stimmen, dann haben wir hier eine klare 200% Chance und die momentanen Einstiegskurse unter 35€ sind günstig.

Gruss
Cirrusx4

[PolyesterPower [KommA]]

würde mich auch interessieren, verfolge den wert schon seit geraumer zeit

mfg PoP

[Patagonier]

Das Kursziel stammt aus dem Global Biotech Investor. Halte ich auch für realistisch, aber nicht allzu schnell, die Aktie hat sich zuletzt sehr gut entwickelt.

[Cirrusx4]

Danke dir.

Hast du ein paar zusätzliche Backrounddaten zu Onyx?
Über ein kurzes Posting würde ich mich sehr freuen.

Danke
Cirrusx4

[LongTermTom]

Thursday March 2, 7:47 am Eastern Time

Onyx Q4 loss narrows


.....RICHMOND, Calif., March 2 (Reuters) -
...............ONYX PHARMACEUTICALS INC.
...............SUMMARY FINANCIAL INFORMATION
...............STATEMENTS OF OPERATIONS
........(in thousands, except per share amounts) (Unaudited)
........................Three Months Ended.......Year Ended
............................December 31,........December 31,
...........................1999.....1998......1999......1998
Total revenue............$6,601....$2,739....$13,324....$11,314
Operating expenses:
Research and development
...........................7.079....6,074.....23,627....25,383
General and administrative
...........................1,340....1,334.....5,341.....5,275
Total operating expenses
...........................8,419....7,408.....28,968....30,658
Loss from operations.....(1,818)...(4,669)...(15,644)..(19,344)
Interest income, net.......171......343.......842......1,685
Net loss................(1,647)...(4,326)..(14,802)..(17,659)
Basic and diluted net loss
per share...............(0.14)...(0.38)....(1.29)....(1.56)
Shares used in computing
basic and diluted net loss
per share...............11,536...11,423....11,503....11,289




Thursday March 2, 6:30 am Eastern Time

Company Press Release

SOURCE: Onyx Pharmaceuticals Inc.

Onyx Pharmaceuticals Reports 1999
Financial Results and Equity Investment

RICHMOND, Calif., March 2 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX
- news) announced today the results of operations for the fourth quarter and year ended
December 31, 1999. The company also announced the closing of a $5 million equity
investment by Warner-Lambert Company at a share price of $17.89, as the first of two stock
issuances in connection with the collaboration agreement signed in October 1999 for the
co-development of ONYX-015.

The company reported a net loss of $1,647,000, or $0.14 per share for the quarter ended
December 31, 1999 compared with a net loss of $4,326,000, or $0.38 per share for the same
quarter in 1998. For the quarters ended December 31, 1999 and 1998, total revenue was
$6,601,000 and $2,739,000, respectively. Revenue increased in the quarter ended December
31, 1999 by $3,862,000 over the same period last year due primarily to ONYX-015 clinical
development funding provided under the new collaboration agreement with Warner-Lambert
Company. Revenue for both quarters also included amounts earned for research performed
under the company`s collaborations with Warner-Lambert for the cell cycle and inflammation
programs as well as Bayer Corporation for the ras program. While the ras program
transitioned from research funding to co-development of a clinical candidate, in December
1999, we completed the final deliverable under the research portion of the Bayer
collaboration and recognized approximately $1,600,000 of research revenue.

Total operating expenses for the quarters ended December 31, 1999 and 1998 were
$8,419,000 and $7,408,000, respectively. Operating expenses increased in the quarter ended
December 31, 1999 by $1,011,000 over the same period last year due primarily to the
progression of ONYX-015 clinical development and the preparation for Phase III clinical
studies.

For the year ended December 31, 1999, the company reported a net loss of $14,802,000, or
$1.29 per share, compared with a net loss of $17,659,000, or $1.56 per share, for the same
period in 1998. For the years ended December 31, 1999 and 1998, total revenue was
$13,324,000 and $11,314,000, respectively. This revenue represents amounts earned for
research performed under the company`s collaborations with its pharmaceutical partners. The
increase in revenue in 1999 is due primarily to ONYX-015 clinical development funding
provided under the new Warner-Lambert collaboration agreement.

Total operating expenses in 1999 of $28,968,000 were $1,690,000 less than in 1998. This
decrease is primarily attributable to a reduced level of research activities associated with the
transition of the ras program.

``Onyx greatly strengthened its financial position and reduced its burn rate in late 1999
through our collaboration agreement with Warner-Lambert Company to jointly develop and
commercialize Onyx`s Phase III anticancer product, ONYX-015, plus two additional armed
anticancer viruses,`` said Hollings Renton, president and chief executive officer of Onyx
Pharmaceuticals.

As of December 31, 1999, the company had cash, cash equivalents and short-term investments
of approximately $14,463,000. This included a $5 million up-front payment received in the
fourth quarter from Warner-Lambert as part of the ONYX-015 collaboration agreement.

``Since the end of 1999, we raised $18 million through a private placement to four
institutional investors in January, and we received a $5 million equity investment by
Warner-Lambert announced today,`` Mr. Renton added. ``These new financial resources will
allow Onyx to further exploit the potential of our therapeutic virus platform to new products
that selectively kill cancer cells based on specific mutations and on viruses that have been
armed with anticancer genes for enhanced tumor destruction.``

Onyx Pharmaceuticals is discovering, developing and intends to commercialize novel cancer
therapies based on the genetic mutations that cause the disease. The company pursues a
strategy of establishing corporate partnerships that provide complementary skills in chemistry,
drug development, and marketing and sales. The Onyx Web site address is:
www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding the development of
potential human therapeutic products that involve a number of risks and uncertainties. Actual
events may differ from the company`s expectations. In addition to the matters described in this
press release, the timeline for clinical activity, results of pending or future clinical trials,
including the trials of ONYX-015, and changes in the status of the company`s collaborative
relationships, as well as the risk factors listed from time to time in the company`s periodic
reports with the Securities and Exchange Commission, including but not limited to its Annual
Report on Form 10-K, may affect the actual results achieved by the company.

http://biz.yahoo.com/n/o/onxx.html

[Cirrusx4]

Danke dir!

Klingt doch sehr gut.
Bin überzeugt!

Gruß
Cirrusx4